ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Heerdt, P. M.
Right arrow Articles by Weiss, C. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heerdt, P. M.
Right arrow Articles by Weiss, C. I.

The Annals of Thoracic Surgery, Vol 49, 463-465, Copyright © 1990 by The Society of Thoracic Surgeons

ARTICLES

Prostaglandin E1 and intrapulmonary shunt in cardiac surgical patients with pulmonary hypertension [published erratum appears in Ann Thorac Surg 1990 Aug;50(2):337]

PM Heerdt and CI Weiss
Department of Anesthesiology, Washington University School of Medicine, St Louis, Missouri 63110.

Unlike many other vasodilators, prostaglandin E1 may reduce pulmonary vascular resistance without changing intrapulmonary shunt in patients with adult respiratory distress syndrome. Whether the same is true for surgical patients with cardiogenic pulmonary hypertension but normal gas exchange remains unclear. Data from the intraoperative records of 8 patients with pulmonary hypertension and elevated pulmonary vascular resistance were used for the study. Hemodynamic variables had been monitored through radial arterial cannulas and pulmonary arterial catheters. Arterial and mixed venous oxygen tension, carbon dioxide tension, oxygen saturation, and hemoglobin level, as well as cardiac output and pulmonary capillary wedge pressure, had been determined in each patient before prostaglandin E1 infusion was started and again when the desired pulmonary vascular response had been achieved. Pulmonary and systemic vascular resistances and intrapulmonary shunt were calculated from standard formulas. Infusion rates of prostaglandin E1 ranged from 7 to 135 ng/kg/min. Prostaglandin E1 reduced mean pulmonary arterial pressure, pulmonary vascular resistance, and pulmonary capillary wedge pressure but did not change intrapulmonary shunt. Heart rate and mean arterial and right atrial pressures were not changed, whereas systemic vascular resistance decreased and cardiac output increased. The present study shows that prostaglandin E1 reduces pulmonary arterial pressure and pulmonary vascular resistance without dramatic changes in intrapulmonary shunt in patients with pulmonary hypertension secondary to cardiac disease.


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
M. R. Mehrabi, N. Serbecic, F. Tamaddon, C. Kaun, K. Huber, R. Pacher, T. Wild, G. Mall, J. Wojta, and H.-D Glogar
Clinical and experimental evidence of prostaglandin E1-induced angiogenesis in the myocardium of patients with ischemic heart disease
Cardiovasc Res, November 1, 2002; 56(2): 214 - 224.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
Q. Zhou, Y. Lai, H. Wei, R. Song, Y. Wu, and H. Zhang
Unidirectional Valve Patch for Repair of Cardiac Septal Defects With Pulmonary Hypertension
Ann. Thorac. Surg., November 1, 1995; 60(5): 1245 - 1248.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1990 by The Society of Thoracic Surgeons.